Conduit Pharmaceuticals Inc. (CDT)
NASDAQ (CM) NASDAQ (CM) Primary 
CXA 
CDT Equity Inc. (NASDAQ:CDT) Short Interest Update
CDT Equity Inc. (NASDAQ: CDT - Get Free Report) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 177,766 shares, a growth of 140.0% from the February 12th total of 74,063 shares. Approximately 8.4% of the shares of the stock are sold short. Based
CDT Environmental Technology Announces Private Placement of Common Stock
SHENZHEN, China, Jan.
CDT Environmental Technology Reports 2025 Unaudited Interim Financial Results and Provides Business Updates
Revenue of $7.3 million and loss per share of $0.11 impacted by reduced project activity due to a slowdown in the PRC economy SHENZHEN, China, Dec.
CDT Environmental Technology Announces Results of Annual General Meeting
Key Takeaways SHENZHEN, China, Nov.
CDT Environmental Technology Announces New Strategic Growth Initiatives, Enters Clean Energy Market with Waste-to-Hydrogen Technology
Company leverages collaboration with Guangzhou Institute of Energy Conversion, Chinese Academy of Sciences, to convert urban and rural organic waste into green hydrogen SHENZHEN, China, Nov. 20, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – CDT Environmental Technology Investment Holding Co., Ltd.
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is up on Wednesday following a shareholder update concerning a major investor in the company. New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited holds a 14.8% stake in CDT stock.
Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced an exclusive license agreement with AstraZeneca (NASDAQ: AZN ). This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca.
Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is taking off on Tuesday alongside a new patent for the clinical-stage specialty biopharmaceutical company. Conduit Pharmaceuticals notes that it now has an Austrailian patent that covers its HK-4 Glucokinase Activator that targets autoimmune diseases.
